BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9654064)

  • 1. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
    Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
    Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
    Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
    J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
    Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
    J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
    Stefansson S; Lawrence DA
    Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of plasminogen activator inhibitor-1 as inhibitor of platelet and megakaryoblastic cell adhesion.
    Wohn KD; Schmidt T; Kanse SM; Yutzy B; Germer M; Morgenstern E; Preissner KT
    Br J Haematol; 1999 Mar; 104(4):901-8. PubMed ID: 10192457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
    Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
    Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
    Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
    Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
    De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
    EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin.
    Stefansson S; Su EJ; Ishigami S; Cale JM; Gao Y; Gorlatova N; Lawrence DA
    J Biol Chem; 2007 May; 282(21):15679-89. PubMed ID: 17403662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
    Wei Y; Czekay RP; Robillard L; Kugler MC; Zhang F; Kim KK; Xiong JP; Humphries MJ; Chapman HA
    J Cell Biol; 2005 Jan; 168(3):501-11. PubMed ID: 15684035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
    Moser TL; Enghild JJ; Pizzo SV; Stack MS
    Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis.
    Lawrence DA; Palaniappan S; Stefansson S; Olson ST; Francis-Chmura AM; Shore JD; Ginsburg D
    J Biol Chem; 1997 Mar; 272(12):7676-80. PubMed ID: 9065424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin.
    Reinartz J; Schäfer B; Batrla R; Klein CE; Kramer MD
    Exp Cell Res; 1995 Oct; 220(2):274-82. PubMed ID: 7556434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
    Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
    J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
    Brandal S; Blake CM; Sullenger BA; Fortenberry YM
    Nucleic Acid Ther; 2011 Dec; 21(6):373-81. PubMed ID: 22103403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.